CTKB
NASDAQ · Life Sciences Tools & Services
Cytek Biosciences Inc
$3.77
-0.21 (-5.28%)
Financial Highlights (FY 2026)
Revenue
187.76M
Net Income
-62,007,169
Gross Margin
51.8%
Profit Margin
-33.0%
Rev Growth
+7.1%
D/E Ratio
0.02
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 51.8% | 51.8% | 58.3% | 58.3% |
| Operating Margin | -20.0% | -18.0% | 15.6% | 13.4% |
| Profit Margin | -33.0% | -31.4% | 11.9% | 11.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 187.76M | 175.31M | 285.65M | 250.25M |
| Gross Profit | 97.33M | 90.88M | 166.57M | 145.92M |
| Operating Income | -37,626,997 | -31,619,325 | 44.66M | 33.48M |
| Net Income | -62,007,169 | -52,106,864 | 33.87M | 27.85M |
| Gross Margin | 51.8% | 51.8% | 58.3% | 58.3% |
| Operating Margin | -20.0% | -18.0% | 15.6% | 13.4% |
| Profit Margin | -33.0% | -31.4% | 11.9% | 11.1% |
| Rev Growth | +7.1% | +7.1% | +23.4% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 4.77M | 4.77M | 185.65M | 183.29M |
| Total Equity | 238.66M | 238.66M | 348.72M | 320.85M |
| D/E Ratio | 0.02 | 0.02 | 0.53 | 0.57 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -30,569,094 | -27,115,442 | 45.08M | 40.37M |
| Free Cash Flow | — | — | 30.74M | 26.84M |